Using soluble ST2 to predict adverse postoperative outcomes in patients with ımpaired left ventricular function undergoing coronary bypass surgery

dc.authorid0000-0001-9161-2632en_US
dc.contributor.authorDolapoğlu, Ahmet
dc.contributor.authorAvcı, Eyüp
dc.contributor.authorYıldırım, Tarık
dc.contributor.authorKadı, Hasan
dc.contributor.authorÇelik, Ahmet
dc.date.accessioned2020-01-23T12:05:07Z
dc.date.available2020-01-23T12:05:07Z
dc.date.issued2019en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionDolapoğlu, Ahmet (Balikesir Author)en_US
dc.description.abstractBackground and Objectives: The aim of this study was to investigate the prognostic value of soluble ST2 (sST2) in predicting postoperative adverse events in patients with impaired left ventricular (LV) function undergoing coronary artery bypass graft (CABG) surgery. Materials and Methods: This study included 80 consecutive patients with stable coronary artery disease (CAD) and impaired LV function (ejection fraction <= 45%) undergoing on-pump coronary artery bypass graft surgery. The patients were divided into the "high" or "low" group according to their ST2 levels (>= 35 or <35 ng/mL). Results: Postoperative adverse events were more common in patients with high sST2 levels than in patients with low sST2 levels (100% vs 26%, p < 0.0001). Multivariate analysis showed that sST2 level was an independent predictor of the presence of postoperative adverse events (OR: 1.117 (95% CI: 1.016-1.228), p = 0.022). The receiver operating characteristic curve (ROC) analysis of sST2 revealed an area under the curve (AUC) of 0.812 (95% CI: 0.710-0.913, p < 0.001) in predicting postoperative adverse events. An sST2 level of 26.50 ng/ml was identified as the optimal cut-off value, with a sensitivity and specificity of 74.1% and 75.3%, respectively. Conclusion: Higher sST2 levels were associated with adverse outcomes after CABG in patients with impaired LV and stable CAD.en_US
dc.description.sponsorshipMeDar Saglik A.S.en_US
dc.identifier.doi10.3390/medicina55090572
dc.identifier.endpageyoken_US
dc.identifier.issn1010-660X
dc.identifier.issn1648-9144
dc.identifier.issue9en_US
dc.identifier.scopus2-s2.0-85071978757
dc.identifier.scopusqualityQ1
dc.identifier.startpageyoken_US
dc.identifier.urihttps://doi.org/10.3390/medicina55090572
dc.identifier.urihttps://hdl.handle.net/20.500.12462/10550
dc.identifier.volume55en_US
dc.identifier.wosWOS:000490752800065
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherMDPIen_US
dc.relation.ispartofMedicina-Lithuaniaen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectSoluble ST2en_US
dc.subjectCoronary Artery Bypass Graft Surgeryen_US
dc.subjectPostoperative Adverse Eventsen_US
dc.titleUsing soluble ST2 to predict adverse postoperative outcomes in patients with ımpaired left ventricular function undergoing coronary bypass surgeryen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Using_Soluble_ST2_to_Predict_Adverse_Postoperative.pdf
Boyut:
429.12 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text

Lisans paketi

Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: